Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: A report of 78 cases

Yan Xia Yu, Yuan Kai Shi, Xiao Hui He, Li Qiang Zhou, Sheng Yu Zhou, Mei Dong, Feng Yi Feng, Yan Sun

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objective: To summarize the clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified (PTCL-US). Methods: The medical records of 78 patients with PTCL-US classified according to the revised European and American lymphoma (REAL) or WHO criteria, 58 males and 20 females, aged 39 (9 - 75), 46 of them (59%) being at the stages III/VI and 40 cases (51.2%) with extranodal involvement), treated from Jan 1994 to Dec 2004 in the Cancer Hospital/ Institute, Chinese Academy of Medical Sciences, were retrospectively analyzed. The patients were followed up for 58 months. Results: Thirty patients (38%) were with high level lactate dehydrogenase (LDH). 34 cases (43.7%) were treated with chemoradiotherapy, and 43 (55%) with chemotherapy alone. After the first line treatment the complete recovery (CR) rate and partial recovery (PR) rate were 55.1% (43/78) and 25.6% (20/78) respectively. 15 cases (19.2%) showed progressive disease (PD) or stable disease (SD). Achieving CR or PR after first-line treatment, 13 cases received autologous peripheral blood stem cell transplantation (APBSCT). The 5-year overall survival rate (OS) and 5-year progressive-free survival rate (PFS) were 41.4% and 33.8% respectively. The 5-year OS of the CR, PR, and PD/SD groups were 65.1%, 21.9%, and 0% respectively. The 5-year OS for the patients treated with first-line APBSCT was 61.5%, not significantly different from that of the patients treated with conventional dose therapy alone (52.3%, P = 0.894). Univariate analysis showed that the factors associated with a worse OS included stage III/IV (P = 0.001), high LDH (P = 0.0001), behavior state score ≥2 (P = 0.001), and bone marrow involvement (P = 0.011). Multivariate analysis showed that LDH level was an independent factor predictive of survival (P = 0.001). International prognostic index and prognostic index for peripheral T-cell lymphoma both predicted the overall survival. Conclusion: A rare lymphoma with aggressive presentation, PTCL-US responds poorly to conventional treatment. The prognosis of the cases with high risk is bad. APBSCT is safe and feasible when CR or PR is achieved after first line treatment.

Original languageEnglish
Pages (from-to)2714-2716
Number of pages3
JournalNational Medical Journal of China
Issue number38
StatePublished - Oct 16 2007


  • Hematopoietic stem cell transplantation
  • Lymphoma, T-cell, peripheral
  • Prognosis


Dive into the research topics of 'Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: A report of 78 cases'. Together they form a unique fingerprint.

Cite this